Elranatamab, now Elrexfio, approved for hard-to-treat myeloma
The U.S. Food and Drug Administration (FDA) has granted conditional approval to Pfizer‘s elranatamab — an antibody therapy to be marketed under the brand…
Lindsey Shapiro, PhD, science writer — 
Articles by Lindsey Shapiro
2 Janssen therapies for RRMM earn positive opinion from EU committee
A European Medicines Agency committee has recommended that one antibody-based cancer therapy from Janssen Pharmaceuticals be approved for the treatment of relapsed and refractory…
Next IMF Patient and Family Seminar slated for Aug. 18-19 in LA
The International Myeloma Foundation (IMF) will host its second in-person Patient and Family Seminar of the year on Aug. 18-19 in Los Angeles.
FDA asked to extend Carvykti to myeloma patients after first relapse
Janssen is asking the U.S. Food and Drug Administration (FDA) to expand approval its cell therapy Carvykti (ciltacabtagene autoleucel) to allow for earlier…
ISB 1442 antibody therapy wins US orphan drug status
ISB 1442, Ichnos Sciences’Â investigational bi-specific antibody-based treatment, has earned orphan drug designation from the U.S. Food and Drug Administration (FDA) for treating relapsed or…
EasyM, blood test for residual myeloma activity, certified in US
Multiple myeloma patients in the U.S. will now have access to Rapid Novor‘s noninvasive and highly sensitive blood test for monitoring minimal residual…
IASO Biotherapeutics’ CAR T-cell therapy gets fresh FDA support
The U.S. Food and Drug Administration (FDA) has granted fast track and regenerative medicine advanced therapy designations to CT103A, IASO Biotherapeutics’ experimental CAR T-cell therapy…
Worse Prognosis Found for Obese, Underweight Myeloma Patients
Extremes in body mass index (BMI) — a ratio of weight to height that’s used to estimate a person’s healthy weight — are associated with…
Data: Revlimid Triple Combo Is Better as Myeloma Maintenance Therapy
In people with newly diagnosed multiple myeloma following a stem cell transplant, a triple-combination maintenance therapy — of Revlimid (lenalidomide), Kyprolis (carfilzomib)…
MCARH109, CAR T-cell Therapy for Advanced MM, Shows Potential
A new investigational CAR T-cell therapy, called MCARH109, demonstrated an ability to shrink or eliminate the amount of cancer in patients with relapsed or refractory…
